COMMERCIALISING INNOVATIVE TECHNOLOGY

The Photon UVC uses a 5 second dose of UVC light to kill bacterial infections. Smallfry played a pivotal role in sourcing and configuring a UVC source at a precisely controlled wavelength and power to deliver a safe and targeted treatment. The wavelength of UVC used has been shown to be as safe as UVA (the familiar ‘Blacklight’ used in nightclubs), however it is naturally blocked by the Earth’s atmosphere, meaning we are not normally exposed to it. Consequently, microbes have no resistance and are completely neutralised.

Working with Photon Therapeutic’s own pioneering experts in ophthalmic research and clinical science we were able to drive this initiative forward into its first commercial application. Like any new innovation, the challenge lay in striking the right balance between desirability, feasibility and commercial viability.

Our dedicated team worked tirelessly to transform this technology into an ergonomic, handheld product that puts user experience at the forefront whilst conveying a high perceived value appropriate for a professional, high value medical device.

CREATING A VISUAL BRAND LANGUAGE

As a first commercial application of a new technology, Photon were keen to have a design that set out their future ambitions with a Visual Brand Language (VBL) that conveyed precision, confidence and cutting-edge technology, aligning with their business goals and customer expectations.

The design needed to stand out and resonate with the entire team to help attract new customers, distribution partners and investment. To achieve this the design showcases a sleek, clinical form, complemented by contrasting colours that emphasise soft edges and flowing chamfers, carefully balanced in the hand and good to hold.

The Graphical User Interface (GUI) was developed to provide intuitive access to the key functions so treatment can be safely administered within seconds with minimal training.

BALANCING TECHNOLOGY AND USABILITY

A key challenge for producing an effective device was delivering a highly-consistent dose of UV treatment across the target area of the eye. Having identified a precisely controlled UV source we were able to create an optical arrangement that produced an even spread of light therapy contained within the boundary of a defined treatment area.

To ensure the device was easy to use, without patient contact, device positioning and distancing are controlled through video feedback from a focus-controlled camera. The elements are carefully arranged to give a natural and intuitive user experience that reduces training for effective use to just a few minutes.

Through a series of development electronics, mechanical test rigs, and prototype builds, Smallfry optimised the design to ensure a smooth transition to production with proven efficacy.

ATTENTION TO DETAIL

Ensuring a successful implementation of research technology into a commercially viable product requires meticulous attention to detail. This focus was evident in every phase of the Photon project, from selecting reputable manufacturers to conducting thorough audits that verified essential capabilities and quality standards.

We employed a rigorous process to engage only the most competent suppliers. This thorough approach not only facilitated seamless market integration but also reinforced the exceptional quality and reliability of the Photon UVC.

Ultimately, it is our diligence and expertise in every facet of a project that cements our reputation as leaders in transforming innovative research into successful market solutions.

ONGOING DEVELOPMENT

Smallfry continues to collaborate with Photon to bring the product to market, ready to launch at the London Vet Show in November 2024.

Photon Therapeutics was recently recognised as the winner of the Innovation Session at ESCRS iNovation® Day in Barcelona, where attendees were asked which emerging technologies would have the most significant potential impact on ophthalmic practices and patients in the near future.